 LA JOLLA, Calif., May 05, 2021 GLOBE NEWSWIRE -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market NASDAQ:MNOV and the JASDAQ Market of the Tokyo Stock Exchange Code Number: 4875, today announced that it has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers the combination of MN-166 ibudilast and riluzole for the treatment of amyotrophic lateral sclerosis ALS. 